Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
PowderMed |
---|---|
Information provided by: | PowderMed |
ClinicalTrials.gov Identifier: | NCT00310271 |
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing. The study will also test the ability of vaccine to cause particular immune responses in the body.
Condition | Intervention | Phase |
---|---|---|
HSV-2 |
Biological: pPJV7630 with pPJV2012 administered by PMED |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety Study |
Official Title: | A Phase I Study Assessing Safety and Tolerability of a DNA Vaccine With a DNA Encoded Immunostimulator , Administered by Particle Mediated Epidermal Delivery Using the PowderMed ND10 Delivery System in HSV-2 Seronegative Healthy Volunteers |
Estimated Enrollment: | 42 |
Study Start Date: | April 2006 |
Estimated Study Completion Date: | December 2006 |
Herpes simplex virus type 2 (HSV-2) infection is a serious public health problem, with up to 20% of the US population infected. Following primary infection, HSV-2 establishes a latent infection that can lead to recurrent disease when the virus reactivates. Genital lesions are often experienced with viral recurrence and these can be uncomfortable and painful, resulting in significant anxiety and social distress. There are no commercial vaccines available for therapy of HSV-2 infection.The aim of a therapeutic vaccine would be to enhance such natural responses by boosting the appropriate cellular immune response to HSV-2 in those latently infected individuals who experience frequent and unwanted reactivations. The purpose of this study is to evaluate the safety and tolerability profile of a therapeutic DNA vaccine (pPJV7630) in combination with a DNA encoded immunostimulator (pPJV2012) when administered by Particle Mediated Epidermal Delivery (PMED)
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Otherwise healthy subjects with seronegative HSV-2
Study ID Numbers: | PM HSD-001 P |
Study First Received: | March 31, 2006 |
Last Updated: | November 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00310271 History of Changes |
Health Authority: | United States: Food and Drug Administration |
DNA vaccine, immunotherapy, HSV-2, PMED |
Sennoside A&B Senna Extract Healthy |